VRAX — VIRAX BIOLABS GROUP LTD
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
华尔街分析师共识
评级、12 个月目标价与 EPS 预期,来自 Nasdaq 公开分析师数据接口。 · 抓取于 2026-11-19
前瞻市盈率 = 抓取时现价 ÷ 共识 EPS(季度数据 ×4 年化)。修正分 =(上调 − 下调)÷ 预测机构数,来自 Nasdaq 近 4 周统计。 来源: Nasdaq analyst data
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
截至Q3 2026,共 4 家机构在其最新 13F 申报中持有 VRAX(VIRAX BIOLABS GROUP LTD),合计申报市值 $72.43K,对应 33.16K 股。按股数计算较上季度增持 25.7%(+6.77K 股),申报市值环比下降 6.7%。持仓集中度较高:前五大持有人占申报市值的 100.0%,前十大的集中度为 100.0%。
与上一季度相比,2 家新建仓位、2 家加仓。13F 数据为季末快照,以上变动反映的是 Q3 2026 末的持仓状态,并非实时交易。
VIRAX BIOLABS GROUP LTD(VRAX)的主要机构持有人包括 Renaissance Technologies、ARMISTICE CAPITAL, LLC、Squarepoint Ops LLC,按 13F 申报市值在本页 28 家持有人中排名居前。
VRAX 属于Health Care板块。
本页所有数据均来自美国证监会(SEC)13F 季度申报。13F 申报人需在季度结束后 45 天内披露 10 万美元以上的多头持仓;空头、期权对冲与季度内交易不在其列,因此这些数字反映的是机构持仓的季度快照,而非实时仓位。
机构逐季持仓趋势
| 季度 | 持有机构数 | 股数 | 金额 | 环比净变动 |
|---|---|---|---|---|
| Q3 2026 | 4 | 33.16K | $72.43K | +25.7% |
| Q2 2026 | 2 | 26.39K | $77.58K | — |
| Q1 2026 | 4 | 919.57K | $202.21K | +0.0% |
| Q4 2025 | 6 | 34.98K | $12.09K | +1.0% |
| Q3 2025 | 5 | 94.83K | $57.06K | +100.0% |
| Q2 2025 | 2 | 35.16K | $28.62K | +122.7% |
| Q1 2025 | 4 | 63.10K | $71.53K | -40.9% |
| Q4 2024 | 7 | 63.01K | $141.37K | +84.7% |
表内 8 个季度中,机构持股合计减少 47%(Q4 2024 → Q3 2026);单季变动最大的是 Q2 2025(+122.7%)。
前 25 大机构持仓人(Q3 2026) — 4 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 32.90K | $71.86K | 0.00% | 增持 | |
| 257 | $561 | 0.00% | 增持 | |
| 3 | $7 | 0.00% | 新进 | |
| 2 | $4 | 0.00% | 新进 |
更早季度的机构持仓记录(逐季列表): 返回前 25 大机构持仓人
Q2 2026 — 2 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 26.39K | $77.57K | 0.00% | 新进 | |
| 4 | $12 | 0.00% | 新进 |
Q1 2026 — 4 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 878.80K | $193.25K | 0.00% | 新进 | |
| 40.72K | $8.96K | 0.00% | 新进 | |
| 21 | $4 | 0.00% | 持有 | |
| 20 | $4 | 0.00% | 持有 |
Q4 2025 — 6 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 21.44K | $7.41K | 0.00% | 新进 | |
| 7.49K | $2.59K | 0.00% | 增持 | |
| 6.00K | $2.07K | 0.00% | 减持 | |
| 21 | $7 | 0.00% | 持有 | |
| 20 | $7 | 0.00% | 新进 | |
| 10 | $3 | 0.00% | 新进 |
Q3 2025 — 5 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 60.07K | $36.00K | 0.00% | 新进 | |
| 21.38K | $13.00K | 0.00% | 新进 | |
| 10.00K | $6.00K | 0.00% | 增持 | |
| 3.36K | $2.04K | 0.00% | 新进 | |
| 21 | $13 | 0.00% | 新进 |
Q2 2025 — 2 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 30.16K | $24.67K | 0.00% | 增持 | |
| 5.00K | $3.95K | 0.00% | 新进 |
新建仓(Q3 2026)
- Caitong International Asset Management Co., Ltd 3 股 · $7
- JPMorgan Chase & Co 2 股 · $4
完全清仓(较上季)
本季度没有被追踪基金完全清仓。
基金持仓历史 — 各季度股数(前 20 只基金)
| 基金 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JANE STREET GROUP, LLC | 32.90K | 26.39K | — | — | — | — | — | — | 11.63K | — | — | — | — | — | — | — | — |
| UBS Group AG | 257 | 4 | — | 7.49K | 3.36K | — | 22.43K | 37.91K | 20.53K | 5.60K | 2.58K | 665 | 147 | — | 3.07K | 6.18K | 12.20K |
| Caitong International Asset Management Co., Ltd | 3 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| JPMorgan Chase & Co | 2 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Renaissance Technologies | — | — | — | — | — | — | — | — | 145.40K | 11.00K | — | — | — | 24.60K | — | 11.40K | — |
| ARMISTICE CAPITAL, LLC | — | — | 878.80K | — | — | — | — | — | — | — | — | 122.00K | — | — | — | — | — |
| Squarepoint Ops LLC | — | — | — | — | — | — | — | — | 40.62K | — | — | — | — | — | — | — | — |
| Legal & General Investment Management America | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 99.76K | 102.61K | — |
| HRT FINANCIAL LP | — | — | — | — | 60.07K | — | 13.51K | — | — | 25.67K | — | — | — | — | — | — | — |
| Virtu Financial LLC | — | — | — | — | 21.38K | — | — | — | — | 28.06K | — | 10.64K | — | — | — | — | — |
| XTX Topco Ltd | — | — | — | 21.44K | — | — | — | 11.86K | — | — | — | — | — | — | — | — | — |
| Citadel Advisors | — | — | — | — | — | 30.16K | 13.54K | — | — | — | 14.79K | — | 16.36K | — | — | — | — |
| ROYAL BANK OF CANADA | — | — | — | — | — | — | — | 10.40K | — | — | — | — | — | — | — | — | — |
| TWO SIGMA SECURITIES, LLC | — | — | — | — | — | — | 13.63K | — | — | — | — | — | — | — | — | — | — |
| Jump Financial, LLC | — | — | 40.72K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| R Squared Ltd | — | — | — | — | — | — | — | 2.70K | — | — | — | — | — | — | — | — | — |
| NATIONAL BANK OF CANADA /FI/ | — | — | — | 6.00K | 10.00K | 5.00K | — | — | — | — | — | — | — | — | — | — | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | — | — | — | — | — | — | — | — | — | — | — | — | 15.00K | — | — | — | — |
| Wells Fargo & Co | — | — | — | — | — | — | — | — | — | 100 | 100 | 200 | 2.00K | 2.00K | — | — | — |
| Headlands Technologies LLC | — | — | — | — | — | — | — | — | 185 | 45 | — | — | — | — | — | — | — |
▲ 低买(基金新建/增持,下一季股价上涨 ≥5%) ▼ 高卖(基金减持,下一季股价下跌 ≥5%)
拖拽/滚轮缩放 · 默认显示最近一年 · 标注来自 13F 申报中的季度基金操作 · 悬停查看详情
常见问题
Which funds hold VRAX?
As of 2026-Q3, 4 institutional funds reported holding VRAX (VIRAX BIOLABS GROUP LTD) in SEC 13F filings, with a combined reported value of $72.43K.
How many shares of VRAX do institutions own?
13F filers reported 33.16K shares of VRAX, worth $72.43K in aggregate at the end of 2026-Q3.
Is institutional ownership of VRAX rising or falling?
Share counts moved +25.7% versus the prior quarter — accumulation.
Who are the top institutional holders of VRAX?
The largest 13F holders are Renaissance Technologies, ARMISTICE CAPITAL, LLC, Squarepoint Ops LLC, JANE STREET GROUP, LLC, Legal & General Investment Management America; the top 25 are ranked at the top of this page.
Who are the major shareholders of VIRAX BIOLABS GROUP LTD?
The major shareholders of VIRAX BIOLABS GROUP LTD (VRAX) by reported 13F value are Renaissance Technologies, ARMISTICE CAPITAL, LLC, Squarepoint Ops LLC, JANE STREET GROUP, LLC, Legal & General Investment Management America, among 28 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.